How much does the Indian version of Sotorasib cost?

As of now, India has not launched a generic version of Sotorasib (Sotorasib), so there is no "Indian version of Sotorasib" available for purchase on the market. As a targeted drug targeting the KRAS G12C mutation, sotorasiib is a relatively new innovative drug in the world. The patent is still within the protection period. Therefore, major generic drug production countries such as India have not yet produced legal generic versions of the drug. For domestic patients, if they need to use sotoraxib, they still need to rely on overseas channels to obtain original drugs or generic drugs produced in other countries.

Currently, sotoracib is not yet available in mainland China, so domestic patients cannot purchase the drug directly through hospitals or pharmacies. Original drugs are mainly sourced from the European market or Hong Kong, China, and are expensive. The price of each box is often more than tens of thousands of yuan, and the specifications are mostly 120mg*56 tablets. For most patients, the cost of such drugs is high, especially if long-term use is required, and the financial burden is very heavy.

In comparison, the generic version already on the market in Laos has become an economical alternative for many patients. The price of generic drugs of Sotorasibu, produced by Laos Lusun (Lusun) and Laos Bear (Bear), has been significantly reduced in recent years. Currently, a box of 120mg*56 tablets sells for only more than 1,000 yuan. These generic drugs are basically the same as the original drugs in terms of drug composition and mechanism of action. Although they do not have the full certification of the original drugs in all clinical studies, they have received positive feedback from many patients in actual use.

In summary, there is currently no Indian generic version of sotoraxib. Patients who wish to obtain the drug at a more affordable price may consider Laotian generics as an alternative. Before using generic drugs, it is recommended that patients communicate with their attending doctors to evaluate the suitability of treatment and ensure that the drugs are obtained through formal channels to ensure safety and efficacy. At the same time, we will continue to pay attention to the launch progress of this drug in mainland China. If it can enter the medical insurance system in the future, more patients will be able to benefit from it.

Reference materials:https://www.lumakras.com/